Patients curious about medical marijuana treatments

Ever since medical marijuana became legal in Illinois on Jan. 1, Loyola University Medical Center neurologist and multiple sclerosis specialist Dr. Matthew McCoyd has been inundated with questions from his patients.

The topic typically comes up at the end of the visit, when the patient brings up one last thing: What does Dr. McCoyd think about ?

"It's an extremely common question," McCoyd said.

There are anecdotal reports that marijuana can relieve pain and spasticity in MS patients, but there is little evidence from clinical trials that marijuana is effective, McCoyd said. However, he noted that a marijuana-based drug called Sativex has been approved in Britain, Canada and other countries for the treatment of MS spasticity. A small pump delivers a precise amount of the peppermint-flavored medicine with each spray. The drug, extracted from cannabis plants, has been shown in to be effective.

McCoyd said medical marijuana may be an option for carefully selected MS patients who are Illinois residents. Like any prescription medication, there is a concern for medication abuse, which will have to be considered on a case-by-case basis.

McCoyd said medical marijuana could also be prescribed to help relieve muscle spasms in patients with (ALS), often referred to as Lou Gehrig's disease, another qualifying medical condition under the new law.

On Jan. 1, Illinois began a four-year trial program that will allow with MS and certain other conditions to obtain prescriptions for medical marijuana. MS is among the main indications for medical marijuana.

McCoyd said there are differences between medical marijuana and marijuana sold on the street. Street marijuana has higher concentrations of THC, the compound that provides the drug's high. Medical marijuana has less THC and higher concentrations of cannabinoid compounds.

add to favorites email to friend print save as pdf

Related Stories

First cannabis-derived drug authorised for France

Jan 09, 2014

France has for the first time approved prescription use of a drug derived from cannabis—a mouth spray used to treat multiple sclerosis (MS) symptoms, the government said Thursday.

Recommended for you

Smoking out the facts in the E-cigarette debate

32 minutes ago

Electronic cigarettes seem to have become as ubiquitous as the vapor they produce. Their popularity has been skyrocketing over the past two years, even in the midst of a fierce debate about their potential ...

Women, work and the menopause

1 hour ago

Menopausal women fear age-based discrimination in the workplace and face a glaring lack of menopause-specific support, according to new research.

Cohabiting couples differ on contraceptive use by class

3 hours ago

Most cohabiting couples intend to delay childbirth until they're married, steadily employed and financially stable. Despite these preferences, surprise pregnancies are common, particularly among working-class men and women ...

Nurse turnover assessments inconsistent

3 hours ago

(HealthDay)—More than 17 percent of new nurses leave their first job within one year of starting, according to research published online Aug. 25 in Policy, Politics, & Nursing Practice.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

norman_gooding
not rated yet Jan 16, 2014
Until the federal government removes cannabis from schedule 1 of the CSA most accredited medical colleges will not chance losing federal funding teaching doctors and healthcare specialist the use and methods of treatment for cannabis as a medicine.
The hypocrisy of the federal government keeping cannabis schedule 1 has existed since it was put there with no scientific proof it belonged there...now over 1 million patients with thousands of doctors recommending it's use is still not accepted medical use.